Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.51 |
| ▸ | FABP7 | O15540 | 2/20 | 0.51 |
| ▸ | FFAR2 | O15552 | 12/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3366299 | 1.00 | FABP5 (0.51) | FABP5FABP7FFAR2KMT2A | |
| SCHEMBL31159434 | 1.00 | FABP5 (0.51) | FABP5FABP7FFAR2KMT2A | |
| Fluoride SCHEMBL7821537 | 0.99 | FABP5 (0.50) | FABP5FABP7FFAR2KMT2A | |
| SCHEMBL31370144 | 0.93 | FABP5 (0.49) | FABP5FABP7FFAR2KMT2A | |
| SCHEMBL31369486 | 0.92 | ACE (0.47) | FABP5FABP7FFAR2 | |
| SCHEMBL13259973 | 0.91 | FABP5 (0.46) | FABP5FABP7FFAR2KMT2A | |
| SCHEMBL31369417 | 0.89 | FFAR2 (0.44) | FABP5FABP7FFAR2 | |
| SCHEMBL31370160 | 0.88 | FFAR2 (0.41) | FABP5FABP7FFAR2 | |
| SCHEMBL31369524 | 0.87 | FFAR2 (0.56) | FABP5FABP7FFAR2 | |
| SCHEMBL8124433 | 0.85 | FABP5 (0.49) | FABP5FABP7FFAR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010100297-A1 | BISTHIAZOLE COMPOUNDS THAT CAN BE USED TO TREAT CANCER | UNIVERSIDAD DE BARCELONA (ES) | 2010-09-10 | — | — | WO | claimed |
| US-9150899-B2 | Identification of compounds modifying a cellular response | 2CUREX (DK) | 2015-10-06 | — | — | US | disclosed |
| US-20130123140-A1 | IDENTIFICATION OF COMPOUNDS MODIFYING A CELLULAR RESPONSE | 2CUREX (DK) | 2013-05-16 | — | — | US | disclosed |
| US-8410028-B2 | Methods for synthesis of encoded libraries | GLAXOSMITHKLINE LLC (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410028-B2 | Methods for synthesis of encoded libraries | GLAXOSMITHKLINE LLC (US) | 2013-04-02 | — | — | US | disclosed |
| US-8318717-B2 | Tetrapeptide capable of inhibiting binding of the Smac protein to Inhibitors of apoptosis, thus promoting apoptosis or sensitizing cells; antiproliferative and anticarcinogenic agents | 2CUREX (DK) | 2012-11-27 | — | — | US | disclosed |
| US-20120245040-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | GLAXOSMITHKLINE (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245040-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | GLAXOSMITHKLINE (US) | 2012-09-27 | — | — | US | disclosed |
| EP-2457896-A1 | Tripeptides as caspase modulators | Idun Pharmaceuticals, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| EP-2457895-A1 | Tetrapeptide analogs | Idun Pharmaceuticals, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20080194537-A1 | Compounds Modifying Apoptosis | 2CUREX (DK) | 2008-08-14 | — | — | US | disclosed |
| US-20070224607-A1 | Methods for identifying compounds of interest using encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070224607-A1 | Methods for identifying compounds of interest using encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2007-09-27 | — | — | US | disclosed |
| EP-1773348-A2 | TETRAPEPTIDE ANALOGS | Idun Pharmaceuticals, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20070042401-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070042401-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2006017295-A2 | TETRAPEPTIDE ANALOGS | IDUN PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20030050248-A1 | Novel amino acid and peptide inhibitors of Staphylococcus virulence | PANORAMA RESEARCH, INC. | 2003-03-13 | — | — | US | disclosed |
| EP-1261362-A2 | NOVEL AMINO ACID AND PEPTIDE INHIBITORS OF STAPHYLOCOCCUS VIRULENCE | Intermune, Inc. (US) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001058471-A2 | NOVEL AMINO ACID AND PEPTIDE INHIBITORS OF STAPHYLOCOCCUS VIRULENCE | INTERMUNE, INC. (US) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245040-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | RNGTT, DTYMK, DUT | FABP5 2281/4885FABP7 2825/4885FFAR2 4704/4885 |
| US-20080194537-A1 | Compounds Modifying Apoptosis | API5, BAX, BAD | FABP5 618/4885FABP7 2332/4885FFAR2 4631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.